Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVR NASDAQ:LUCD NASDAQ:SMTI NASDAQ:ZYXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$6.58+1.1%$5.90$2.85▼$6.95$632.98M1.32693,476 shs599,641 shsLUCDLucid Diagnostics$1.03-1.9%$1.25$0.95▼$1.70$205.02M1.1921,575 shs761,524 shsSMTISanara MedTech$18.40-3.6%$18.82$16.05▼$35.95$174.86M1.1643,868 shs17,658 shsZYXIZynex$0.13$0.12$0.12▼$2.82$3.80M0.992.32 million shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global0.00%+5.85%+19.67%+18.58%+61.54%LUCDLucid Diagnostics0.00%-1.87%-6.25%-13.93%-12.13%SMTISanara MedTech0.00%+0.47%+12.24%-5.73%-40.08%ZYXIZynex0.00%0.00%0.00%+125.84%-93.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$6.58+1.1%$5.90$2.85▼$6.95$632.98M1.32693,476 shs599,641 shsLUCDLucid Diagnostics$1.03-1.9%$1.25$0.95▼$1.70$205.02M1.1921,575 shs761,524 shsSMTISanara MedTech$18.40-3.6%$18.82$16.05▼$35.95$174.86M1.1643,868 shs17,658 shsZYXIZynex$0.13$0.12$0.12▼$2.82$3.80M0.992.32 million shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global0.00%+5.85%+19.67%+18.58%+61.54%LUCDLucid Diagnostics0.00%-1.87%-6.25%-13.93%-12.13%SMTISanara MedTech0.00%+0.47%+12.24%-5.73%-40.08%ZYXIZynex0.00%0.00%0.00%+125.84%-93.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVRAnteris Technologies Global 2.50Moderate Buy$15.33133.03% UpsideLUCDLucid Diagnostics 2.60Moderate Buy$4.13300.49% UpsideSMTISanara MedTech 2.25Hold$34.0084.78% UpsideZYXIZynex 2.00Hold$4.903,820.00% UpsideCurrent Analyst Ratings BreakdownLatest LUCD, SMTI, AVR, and ZYXI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026LUCDLucid Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SMTISanara MedTech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026SMTISanara MedTech Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.004/9/2026LUCDLucid Diagnostics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.25 ➝ $9.003/30/2026LUCDLucid Diagnostics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.503/27/2026AVRAnteris Technologies Global Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$15.003/26/2026LUCDLucid Diagnostics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.003/12/2026AVRAnteris Technologies Global Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$15.003/11/2026AVRAnteris Technologies Global Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.003/4/2026AVRAnteris Technologies Global Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$1.91M334.96N/AN/A($0.01) per share-658.00LUCDLucid Diagnostics$4.71M42.70N/AN/A($0.31) per share-3.32SMTISanara MedTech$103.12M1.63$0.57 per share32.09$0.67 per share27.46ZYXIZynex$108.20M0.04$0.25 per share0.51$1.12 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies Global-$94.14M-$2.56N/AN/AN/A-4,921.27%-536.04%-267.57%5/12/2026 (Estimated)LUCDLucid Diagnostics-$58.01M-$0.96N/AN/AN/A-1,426.27%N/A-95.51%5/14/2026 (Estimated)SMTISanara MedTech-$37.56M-$4.23N/AN/AN/A-36.42%-20.73%-5.14%5/12/2026 (Estimated)ZYXIZynex$2.99M-$2.43N/A0.27N/A-68.35%-804.30%-36.67%N/ALatest LUCD, SMTI, AVR, and ZYXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LUCDLucid Diagnostics-$0.05N/AN/AN/A$1.38 millionN/A5/12/2026Q1 2026AVRAnteris Technologies Global-$0.2708N/AN/AN/A$0.77 millionN/A5/12/2026Q1 2026SMTISanara MedTech-$0.13N/AN/AN/A$26.80 millionN/A3/25/2026Q4 2025LUCDLucid Diagnostics-$0.07-$0.10-$0.03-$0.12$1.39 million$1.50 million3/24/2026Q4 2025SMTISanara MedTech$0.11$0.04-$0.07-$0.19$27.90 million$27.55 million2/26/2026H2 2025AVRAnteris Technologies GlobalN/A-$0.75N/A-$0.75N/A$0.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/AZYXIZynexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies Global0.010.730.73LUCDLucid DiagnosticsN/A1.311.30SMTISanara MedTech7.751.801.59ZYXIZynex0.560.470.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ALUCDLucid Diagnostics74.01%SMTISanara MedTech8.10%ZYXIZynex29.68%Insider OwnershipCompanyInsider OwnershipAVRAnteris Technologies Global4.50%LUCDLucid Diagnostics6.80%SMTISanara MedTech42.00%ZYXIZynex49.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13897.23 million92.86 millionN/ALUCDLucid Diagnostics70195.25 million181.98 millionNo DataSMTISanara MedTech609.16 million5.32 millionNot OptionableZYXIZynex77030.39 million15.41 millionOptionableLUCD, SMTI, AVR, and ZYXI HeadlinesRecent News About These CompaniesZYXIQ CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026April 21, 2026 | newsfilecorp.comNZYXIQ INVESTOR ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zynex, Inc.April 16, 2026 | globenewswire.comZYNEX LEAD PLAINTIFF DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Reminds Zynex, Inc Investors to Contact the Firm Before the April 21st Lead Plaintiff DeadlineApril 13, 2026 | globenewswire.comLevi & Korsinsky Notifies Zynex, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ZYXIQApril 13, 2026 | globenewswire.comGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zynex, Inc. (ZYXIQ)April 10, 2026 | globenewswire.comZYXIQ Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Zynex, Inc. Securities Class Action Lawsuit — The Gross Law FirmApril 10, 2026 | globenewswire.comZYXIQ EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026April 9, 2026 | newsfilecorp.comNZYXIQ INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Zynex Investors of Securities Class Action Deadline on April 21, 2026April 3, 2026 | prnewswire.comZYXIQ UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026April 1, 2026 | globenewswire.comZynex, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights - ZYXIQApril 1, 2026 | prnewswire.comZYXI SHAREHOLDER ALERT: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 30, 2026 | prnewswire.comZYXIQ Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Zynex, Inc. Securities Lawsuit — The Gross Law FirmMarch 27, 2026 | globenewswire.comZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 24, 2026 | prnewswire.comZYXIQ CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026March 23, 2026 | newsfilecorp.comNZYXI ALERT: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 20, 2026 | prnewswire.comZYXI SHAREHOLDER NOTICE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 19, 2026 | globenewswire.comShareholders that lost money on Zynex, Inc. (ZYXIQ) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreMarch 18, 2026 | prnewswire.comZYXI INVESTOR ALERT: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud SettlementsMarch 17, 2026 | globenewswire.comZYXIQ UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Zynex Investors of Securities Class Action Deadline on April 21, 2026March 14, 2026 | newsfilecorp.comNHagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following ...March 13, 2026 | bakersfield.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLUCD, SMTI, AVR, and ZYXI Company DescriptionsAnteris Technologies Global NASDAQ:AVR$6.58 +0.07 (+1.08%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$6.68 +0.11 (+1.60%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.Lucid Diagnostics NASDAQ:LUCD$1.03 -0.02 (-1.90%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.06 +0.03 (+2.91%) As of 05/8/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Sanara MedTech NASDAQ:SMTI$18.40 -0.68 (-3.56%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$18.65 +0.25 (+1.36%) As of 05/8/2026 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Zynex NASDAQ:ZYXI$0.12 0.00 (0.00%) As of 05/6/2026Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
